{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T19:55:11Z","timestamp":1778788511007,"version":"3.51.4"},"reference-count":98,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2020,7,3]],"date-time":"2020-07-03T00:00:00Z","timestamp":1593734400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,3]],"date-time":"2020-07-03T00:00:00Z","timestamp":1593734400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s11912-020-00937-4","type":"journal-article","created":{"date-parts":[[2020,7,3]],"date-time":"2020-07-03T01:02:25Z","timestamp":1593738145000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Advances in Molecular Classification and Therapeutic Opportunities in Meningiomas"],"prefix":"10.1007","volume":"22","author":[{"given":"Christine","family":"Cordova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5247-5636","authenticated-orcid":false,"given":"Sylvia C.","family":"Kurz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,7,3]]},"reference":[{"issue":"Supplement_5","key":"937_CR1","doi-asserted-by":"crossref","first-page":"v1","DOI":"10.1093\/neuonc\/noz150","volume":"21","author":"QT Ostrom","year":"2019","unstructured":"Ostrom QT, Cioffi G, Gittleman H, Patil N, Waite K, Kruchko C, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2012\u20132016. Neuro Oncol. 2019;21(Supplement_5):v1\u2013v100.","journal-title":"Neuro Oncol"},{"issue":"3","key":"937_CR2","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s11060-010-0386-3","volume":"99","author":"J Wiemels","year":"2010","unstructured":"Wiemels J, Wrensch M, Claus EB. Epidemiology and etiology of meningioma. J Neuro-Oncol. 2010;99(3):307\u201314.","journal-title":"J Neuro-Oncol"},{"issue":"1","key":"937_CR3","first-page":"4","volume":"122","author":"L Rogers","year":"2015","unstructured":"Rogers L, Barani I, Chamberlain M, Kaley TJ, McDermott M, Raizer J, et al. Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review. 2015;122(1):4.","journal-title":"A RANO review"},{"key":"937_CR4","doi-asserted-by":"publisher","unstructured":"Wen PY, Quant E, Drappatz J, Beroukhim R, Norden AD. Medical therapies for meningiomas. J Neuro-Oncol. 2010;99(3):365\u201378. https:\/\/doi.org\/10.1007\/s11060-010-0349-8.","DOI":"10.1007\/s11060-010-0349-8"},{"issue":"6","key":"937_CR5","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1093\/neuonc\/not330","volume":"16","author":"T Kaley","year":"2014","unstructured":"Kaley T, Barani I, Chamberlain M, McDermott M, Panageas K, Raizer J, et al. Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review. Neuro Oncol. 2014;16(6):829\u201340.","journal-title":"Neuro Oncol."},{"key":"937_CR6","unstructured":"Patil CG, Laws ER. Chapter 1: Meningioma: history of the tumor and its management. In: Pamir M, Black PM, Fahlbusch R, editors. Meningiomas: a comprehensive text; 2010. p. 3\u20139."},{"key":"937_CR7","volume-title":"Histological typing of tumours of the central nervous system","author":"KJ Z\u00fclch","year":"1979","unstructured":"Z\u00fclch KJ. Histological typing of tumours of the central nervous system. Geneva: World Health Organization; 1979."},{"key":"937_CR8","doi-asserted-by":"publisher","unstructured":"Kleihues P, Burger PC, Scheithauer BW. The new WHO classification of brain tumours. Brain Pathol. 1993;3(3):255\u201368. https:\/\/doi.org\/10.1111\/j.1750-3639.1993.tb00752.x.","DOI":"10.1111\/j.1750-3639.1993.tb00752.x"},{"issue":"3","key":"937_CR9","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/jnen\/61.3.215","volume":"61","author":"P Kleihues","year":"2002","unstructured":"Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, Burger PC, et al. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol. 2002;61(3):215\u201325.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"2","key":"937_CR10","first-page":"97","volume":"114","author":"DN Louis","year":"2007","unstructured":"Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous. System. 2007;114(2):97\u2013109.","journal-title":"System."},{"key":"937_CR11","doi-asserted-by":"publisher","unstructured":"Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803\u201320. https:\/\/doi.org\/10.1007\/s00401-016-1545-1.","DOI":"10.1007\/s00401-016-1545-1"},{"key":"937_CR12","doi-asserted-by":"publisher","unstructured":"Ho DM, Hsu CY, Ting LT, Chiang H. Histopathology and MIB-1 labeling index predicted recurrence of meningiomas: a proposal of diagnostic criteria for patients with atypical meningioma. Cancer. 2002;94(5):1538\u201347. https:\/\/doi.org\/10.1002\/cncr.10351.","DOI":"10.1002\/cncr.10351"},{"issue":"5","key":"937_CR13","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.ijrobp.2010.07.039","volume":"81","author":"SE Combs","year":"2011","unstructured":"Combs SE, Schulz-Ertner D, Debus J, von Deimling A, Hartmann C. Improved correlation of the neuropathologic classification according to adapted World Health Organization classification and outcome after radiotherapy in patients with atypical and anaplastic meningiomas. Int J Radiat Oncol Biol Phys. 2011;81(5):1415\u201321.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"937_CR14","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1093\/neuonc\/not325","volume":"16","author":"PH Domingues","year":"2014","unstructured":"Domingues PH, Sousa P, Otero \u00c1, Gon\u00e7alves JM, Ruiz L, de Oliveira C, et al. Proposal for a new risk stratification classification for meningioma based on patient age, WHO tumor grade, size, localization, and karyotype. Neuro Oncol. 2014;16(5):735\u201347.","journal-title":"Neuro Oncol."},{"issue":"3","key":"937_CR15","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/bpa.12174","volume":"25","author":"A Olar","year":"2015","unstructured":"Olar A, Wani KM, Sulman EP, Mansouri A, Zadeh G, Wilson CD, et al. Mitotic index is an independent predictor of recurrence-free survival in meningioma. Brain Pathol. 2015;25(3):266\u201375.","journal-title":"Brain Pathol"},{"issue":"4","key":"937_CR16","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1093\/neuonc\/nov247","volume":"18","author":"CL Rogers","year":"2016","unstructured":"Rogers CL, Perry A, Pugh S, Vogelbaum MA, Brachman D, McMillan W, et al. Pathology concordance levels for meningioma classification and grading in NRG Oncology RTOG Trial 0539. Neuro Oncol. 2016;18(4):565\u201374.","journal-title":"Neuro Oncol."},{"key":"937_CR17","doi-asserted-by":"publisher","unstructured":"Rogers L, Zhang P, Vogelbaum MA, et al. Intermediate-risk meningioma: initial outcomes from NRG Oncology RTOG 0539 [published correction appears in J Neurosurg. 2018 Dec 1;129(6):1650]. J Neurosurg. 2018;129(1):35\u201347. https:\/\/doi.org\/10.3171\/2016.11.JNS161170.","DOI":"10.3171\/2016.11.JNS161170"},{"issue":"3","key":"937_CR18","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/0090-3019(86)90233-8","volume":"25","author":"J J\u00e4\u00e4skel\u00e4inen","year":"1986","unstructured":"J\u00e4\u00e4skel\u00e4inen J, Haltia M, Servo A. Atypical and anaplastic meningiomas: radiology, surgery, radiotherapy, and outcome. Surg Neurol. 1986;25(3):233\u201342.","journal-title":"Surg Neurol"},{"issue":"5","key":"937_CR19","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1093\/neuonc\/nos013","volume":"14","author":"H van Alkemade","year":"2012","unstructured":"van Alkemade H, de Leau M, Dieleman EMT, Kardaun JWPF, van Os R, Vandertop WP, et al. Impaired survival and long-term neurological problems in benign meningioma. Neuro Oncol. 2012;14(5):658\u201366.","journal-title":"Neuro Oncol."},{"key":"937_CR20","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.clineuro.2016.01.006","volume":"141","author":"MJ Gallagher","year":"2016","unstructured":"Gallagher MJ, Jenkinson MD, Brodbelt AR, Mills SJ, Chavredakis E. WHO grade 1 meningioma recurrence: are location and Simpson grade still relevant? Clin Neurol Neurosurg. 2016;141:117\u201321.","journal-title":"Clin Neurol Neurosurg"},{"key":"937_CR21","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.wneu.2015.10.013","volume":"87","author":"A Talacchi","year":"2016","unstructured":"Talacchi A, Muggiolu F, De Carlo A, Nicolato A, Locatelli F, Meglio M. Recurrent atypical meningiomas: combining surgery and radiosurgery in one effective multimodal treatment. World Neurosurg. 2016;87:565\u201372.","journal-title":"World Neurosurg"},{"issue":"8","key":"937_CR22","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1093\/neuonc\/nov069","volume":"17","author":"VR Kshettry","year":"2015","unstructured":"Kshettry VR, Ostrom QT, Kruchko C, Al-Mefty O, Barnett GH, Barnholtz-Sloan JS. Descriptive epidemiology of World Health Organization grades II and III intracranial meningiomas in the United States. Neuro Oncol. 2015;17(8):1166\u201373.","journal-title":"Neuro Oncol."},{"issue":"1","key":"937_CR23","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1136\/jnnp.20.1.22","volume":"20","author":"D Simpson","year":"1957","unstructured":"Simpson D. The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry. 1957;20(1):22\u201339.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"937_CR24","doi-asserted-by":"crossref","first-page":"e588","DOI":"10.1016\/j.wneu.2017.10.028","volume":"109","author":"JS Ehresman","year":"2018","unstructured":"Ehresman JS, Garzon-Muvdi T, Rogers D, Lim M, Gallia GL, Weingart J, et al. The relevance of Simpson grade resections in modern neurosurgical treatment of World Health Organization Grade I, II, and III meningiomas. World Neurosurg. 2018;109:e588\u2013e93.","journal-title":"World Neurosurg"},{"key":"937_CR25","doi-asserted-by":"publisher","unstructured":"Gousias K, Schramm J, Simon M. The Simpson grading revisited: aggressive surgery and its place in modern meningioma management. J Neurosurg. 2016;125(3):551\u201360. https:\/\/doi.org\/10.3171\/2015.9.JNS15754.","DOI":"10.3171\/2015.9.JNS15754"},{"issue":"1","key":"937_CR26","doi-asserted-by":"crossref","first-page":"5944","DOI":"10.1038\/s41598-019-42451-z","volume":"9","author":"J-M Lem\u00e9e","year":"2019","unstructured":"Lem\u00e9e J-M, Corniola MV, Da Broi M, Joswig H, Scheie D, Schaller K, et al. Extent of resection in meningioma: predictive factors and clinical implications. Sci Rep. 2019;9(1):5944.","journal-title":"Sci Rep"},{"issue":"1","key":"937_CR27","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/neuonc\/nou148","volume":"17","author":"TJ Kaley","year":"2015","unstructured":"Kaley TJ, Wen P, Schiff D, Ligon K, Haidar S, Karimi S, et al. Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. Neuro-Oncology. 2015;17(1):116\u201321.","journal-title":"Neuro-Oncology"},{"key":"937_CR28","unstructured":"Network NCC. Central nervous systems Cancer (Version 1.2020).62."},{"issue":"Supplement_3","key":"937_CR29","doi-asserted-by":"crossref","first-page":"iii2","DOI":"10.1093\/neuonc\/noz126.005","volume":"21","author":"M Preusser","year":"2019","unstructured":"Preusser M, Silvani A, Le Rhun E, Soffietti R, Lombardi G, Sepulveda J, et al. PL3.2 Trabectedin for recurrent WHO grade II or III meningioma: a randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG). Neuro Oncol. 2019;21(Supplement_3):iii2\u20133.","journal-title":"Neuro Oncol"},{"issue":"3","key":"937_CR30","first-page":"485","volume":"20","author":"V Barresi","year":"2008","unstructured":"Barresi V, Alafaci C, Salpietro F, Tuccari G. Sstr2A immunohistochemical expression in human meningiomas: is there a correlation with the histological grade, proliferation or microvessel density? Oncol Rep. 2008;20(3):485\u201392.","journal-title":"Oncol Rep"},{"issue":"10","key":"937_CR31","first-page":"13185","volume":"8","author":"CB de Oliveira Silva","year":"2015","unstructured":"de Oliveira Silva CB, Ongaratti BR, Trott G, Haag T, Ferreira NP, Le\u00e3es CGS, et al. Expression of somatostatin receptors (SSTR1-SSTR5) in meningiomas and its clinicopathological significance. Int J Clin Exp Pathol. 2015;8(10):13185\u201392.","journal-title":"Int J Clin Exp Pathol"},{"issue":"1\u20132","key":"937_CR32","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1023\/B:NEON.0000013498.19981.55","volume":"66","author":"S Arena","year":"2004","unstructured":"Arena S, Barbieri F, Thellung S, Pirani P, Corsaro A, Villa V, et al. Expression of somatostatin receptor mRNA in human meningiomas and their implication in in vitro antiproliferative activity. J Neuro Oncol. 2004;66(1\u20132):155\u201366.","journal-title":"J Neuro Oncol"},{"key":"937_CR33","unstructured":"Sharpe C, Duong J, Law WP. 68Ga-DOTATATE PET\/MRI in radiation therapy planning for meningioma \u2013 the benefits of hybrid imaging. J Nucl Med. 2017;58(supplement 1):1111."},{"issue":"Suppl 6","key":"937_CR34","doi-asserted-by":"crossref","first-page":"vi134","DOI":"10.1093\/neuonc\/nox168.550","volume":"19","author":"E Nguyen","year":"2017","unstructured":"Nguyen E, Fu B, Dandekar M, Carrillo J, Kong X-T, Cadena G, et al. MNGI-12. A retrospective interventional cohort study to assess the efficacy and safety of Sandostatin LAR (octreotide acetate) for the treatment of meningiomas in adult patients. Neuro Oncol. 2017;19(Suppl 6):vi134\u2013vi.","journal-title":"Neuro Oncol"},{"issue":"2","key":"937_CR35","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1159\/000448212","volume":"9","author":"A Ortola Buigues","year":"2016","unstructured":"Ortola Buigues A, Crespo Hernandez I, Jorquera Moya M, Diaz Perez JA. Unresectable recurrent multiple meningioma: a case report with radiological response to Somatostatin analogues. Case Rep Oncol. 2016;9(2):520\u20135.","journal-title":"Case Rep Oncol"},{"key":"937_CR36","doi-asserted-by":"publisher","unstructured":"Graillon T, Sanson M, Campello C, et al. Everolimus and octreotide for patients with recurrent meningioma: results from the Phase II CEVOREM Trial. Clin Cancer Res. 2020;26(3):552\u20137. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-2109.","DOI":"10.1158\/1078-0432.CCR-19-2109"},{"issue":"2","key":"937_CR37","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of (177)Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125\u201335.","journal-title":"N Engl J Med"},{"issue":"11","key":"937_CR38","first-page":"1538","volume":"18","author":"K Seystahl","year":"2016","unstructured":"Seystahl K, Stoecklein V, Schuller U, Rushing E, Nicolas G, Schafer N, et al. Somatostatin receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to 68Ga-DOTATATE\/-TOC uptake. Neuro Oncol. 2016;18(11):1538\u201347.","journal-title":"Neuro Oncol"},{"issue":"11","key":"937_CR39","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.2967\/jnumed.115.155853","volume":"56","author":"K Gerster-Gillieron","year":"2015","unstructured":"Gerster-Gillieron K, Forrer F, Maecke H, Mueller-Brand J, Merlo A, Cordier D. 90Y-DOTATOC as a therapeutic option for complex recurrent or progressive Meningiomas. J Nucl Med. 2015;56(11):1748\u201351.","journal-title":"J Nucl Med"},{"issue":"2","key":"937_CR40","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2967\/jnumed.114.147256","volume":"56","author":"N Marincek","year":"2015","unstructured":"Marincek N, Radojewski P, Dumont RA, Brunner P, Muller-Brand J, Maecke HR, et al. Somatostatin receptor-targeted radiopeptide therapy with 90Y-DOTATOC and 177Lu-DOTATOC in progressive meningioma: long-term results of a phase II clinical trial. J Nucl Med. 2015;56(2):171\u20136.","journal-title":"J Nucl Med"},{"issue":"3","key":"937_CR41","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/RLU.0000000000000669","volume":"40","author":"W Makis","year":"2015","unstructured":"Makis W, McCann K, McEwan AJ. Rhabdoid papillary meningioma treated with 177Lu DOTATATE PRRT. Clin Nucl Med. 2015;40(3):237\u201340.","journal-title":"Clin Nucl Med"},{"issue":"3","key":"937_CR42","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.yexmp.2018.10.007","volume":"105","author":"SN McNulty","year":"2018","unstructured":"McNulty SN, Schwetye K, Goldstein M, Carter J, Schmidt RE, Ansstas G, et al. Analysis of point mutations and copy number variation in Grade II and III meningioma. Exp Mol Pathol. 2018;105(3):328\u201333.","journal-title":"Exp Mol Pathol"},{"issue":"5","key":"937_CR43","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/S1470-2045(17)30155-9","volume":"18","author":"F Sahm","year":"2017","unstructured":"Sahm F, Schrimpf D, Stichel D, Jones DTW, Hielscher T, Schefzyk S, et al. DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. Lancet Oncol. 2017;18(5):682\u201394.","journal-title":"Lancet Oncol"},{"issue":"4","key":"937_CR44","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/0092-8674(93)90501-G","volume":"75","author":"JA Trofatter","year":"1993","unstructured":"Trofatter JA, MacCollin MM, Rutter JL, Murrell JR, Duyao MP, Parry DM, et al. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell. 1993;75(4):826.","journal-title":"Cell."},{"issue":"6429","key":"937_CR45","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/363515a0","volume":"363","author":"GA Rouleau","year":"1993","unstructured":"Rouleau GA, Merel P, Lutchman M, Sanson M, Zucman J, Marineau C, et al. Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature. 1993;363(6429):515\u201321.","journal-title":"Nature."},{"key":"937_CR46","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1750-1172-4-16","volume":"4","author":"DGR Evans","year":"2009","unstructured":"Evans DGR. Neurofibromatosis type 2 (NF2): a clinical and molecular review. Orphanet J Rare Dis. 2009;4:16.","journal-title":"Orphanet J Rare Dis"},{"issue":"15","key":"937_CR47","doi-asserted-by":"crossref","first-page":"5419","DOI":"10.1073\/pnas.84.15.5419","volume":"84","author":"BR Seizinger","year":"1987","unstructured":"Seizinger BR, de la Monte S, Atkins L, Gusella JF, Martuza RL. Molecular genetic approach to human meningioma: loss of genes on chromosome 22. Proc Natl Acad Sci U S A. 1987;84(15):5419\u201323.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"937_CR48","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/ng0294-180","volume":"6","author":"MH Ruttledge","year":"1994","unstructured":"Ruttledge MH, Sarrazin J, Rangaratnam S, Phelan CM, Twist E, Merel P, et al. Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas. Nat Genet. 1994;6(2):180\u20134.","journal-title":"Nat Genet"},{"issue":"4","key":"937_CR49","first-page":"827","volume":"146","author":"R Wellenreuther","year":"1995","unstructured":"Wellenreuther R, Kraus JA, Lenartz D, Menon AG, Schramm J, Louis DN, et al. Analysis of the neurofibromatosis 2 gene reveals molecular variants of meningioma. Am J Pathol. 1995;146(4):827\u201332.","journal-title":"Am J Pathol"},{"issue":"1","key":"937_CR50","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1750-3639.2006.tb00557.x","volume":"16","author":"C Hartmann","year":"2006","unstructured":"Hartmann C, Sieberns J, Gehlhaar C, Simon M, Paulus W, von Deimling A. NF2 mutations in secretory and other rare variants of meningiomas. Brain Pathol. 2006;16(1):15\u20139.","journal-title":"Brain Pathol"},{"issue":"3","key":"937_CR51","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/ng.2526","volume":"45","author":"PK Brastianos","year":"2013","unstructured":"Brastianos PK, Horowitz PM, Santagata S, Jones RT, McKenna A, Getz G, et al. Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat Genet. 2013;45(3):285\u20139.","journal-title":"Nat Genet"},{"issue":"2","key":"937_CR52","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.nec.2015.11.009","volume":"27","author":"WL Bi","year":"2016","unstructured":"Bi WL, Mei Y, Agarwalla PK, Beroukhim R, Dunn IF. Genomic and epigenomic landscape in meningioma. Neurosurg Clin N Am. 2016;27(2):167\u201379.","journal-title":"Neurosurg Clin N Am"},{"issue":"1","key":"937_CR53","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s40478-019-0793-4","volume":"7","author":"G Jungwirth","year":"2019","unstructured":"Jungwirth G, Warta R, Beynon C, Sahm F, von Deimling A, Unterberg A, et al. Intraventricular meningiomas frequently harbor NF2 mutations but lack common genetic alterations in TRAF7, AKT1, SMO, KLF4, PIK3CA, and TERT. Acta Neuropathol Commun. 2019;7(1):140.","journal-title":"Acta Neuropathol Commun"},{"issue":"15","key":"937_CR54","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.1128\/MCB.01581-08","volume":"29","author":"MF James","year":"2009","unstructured":"James MF, Han S, Polizzano C, Plotkin SR, Manning BD, Stemmer-Rachamimov AO, et al. NF2\/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth. Mol Cell Biol. 2009;29(15):4250\u201361.","journal-title":"Mol Cell Biol"},{"issue":"5","key":"937_CR55","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1158\/1541-7786.MCR-11-0425-T","volume":"10","author":"MF James","year":"2012","unstructured":"James MF, Stivison E, Beauchamp R, Han S, Li H, Wallace MR, et al. Regulation of mTOR complex 2 signaling in neurofibromatosis 2-deficient target cell types. Mol Cancer Res. 2012;10(5):649\u201359.","journal-title":"Mol Cancer Res"},{"issue":"2","key":"937_CR56","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/sj.bjc.6604002","volume":"98","author":"M Curto","year":"2008","unstructured":"Curto M, McClatchey AI. Nf2\/Merlin: a coordinator of receptor signalling and intercellular contact. Br J Cancer. 2008;98(2):256\u201362.","journal-title":"Br J Cancer"},{"issue":"6","key":"937_CR57","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1136\/jmg.2007.056499","volume":"45","author":"KD Hadfield","year":"2008","unstructured":"Hadfield KD, Newman WG, Bowers NL, Wallace A, Bolger C, Colley A, et al. Molecular characterisation of SMARCB1 and NF2 in familial and sporadic schwannomatosis. J Med Genet. 2008;45(6):332\u20139.","journal-title":"J Med Genet"},{"issue":"237","key":"937_CR58","doi-asserted-by":"crossref","first-page":"237ra68","DOI":"10.1126\/scitranslmed.3008639","volume":"6","author":"IM Shapiro","year":"2014","unstructured":"Shapiro IM, Kolev VN, Vidal CM, Kadariya Y, Ring JE, Wright Q, et al. Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship. Sci Transl Med. 2014;6(237):237ra68.","journal-title":"Sci Transl Med"},{"issue":"6123","key":"937_CR59","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1126\/science.1233009","volume":"339","author":"VE Clark","year":"2013","unstructured":"Clark VE, Erson-Omay EZ, Serin A, Yin J, Cotney J, Ozduman K, et al. Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science. 2013;339(6123):1077\u201380.","journal-title":"Science."},{"issue":"10","key":"937_CR60","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1002\/ajmg.a.37737","volume":"170","author":"KM Keppler-Noreuil","year":"2016","unstructured":"Keppler-Noreuil KM, Baker EH, Sapp JC, Lindhurst MJ, Biesecker LG. Somatic AKT1 mutations cause meningiomas colocalizing with a characteristic pattern of cranial hyperostosis. Am J Med Genet A. 2016;170(10):2605\u201310.","journal-title":"Am J Med Genet A"},{"issue":"8","key":"937_CR61","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1093\/neuonc\/nox018","volume":"19","author":"U Yesiloz","year":"2017","unstructured":"Yesiloz U, Kirches E, Hartmann C, Scholz J, Kropf S, Sahm F, et al. Frequent AKT1E17K mutations in skull base meningiomas are associated with mTOR and ERK1\/2 activation and reduced time to tumor recurrence. Neuro Oncol. 2017;19(8):1088\u201396.","journal-title":"Neuro Oncol"},{"issue":"6","key":"937_CR62","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1055\/s-0038-1676821","volume":"80","author":"SR Williams","year":"2019","unstructured":"Williams SR, Juratli TA, Castro BA, Lazaro TT, Gill CM, Nayyar N, et al. Genomic analysis of posterior Fossa meningioma demonstrates frequent AKT1 E17K mutations in foramen magnum meningiomas. J Neurol Surg B Skull Base. 2019;80(6):562\u20137.","journal-title":"J Neurol Surg B Skull Base"},{"issue":"2","key":"937_CR63","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s11060-016-2172-3","volume":"129","author":"KC Shih","year":"2016","unstructured":"Shih KC, Chowdhary S, Rosenblatt P, Weir AB 3rd, Shepard GC, Williams JT, et al. A phase II trial of bevacizumab and everolimus as treatment for patients with refractory, progressive intracranial meningioma. J Neuro Oncol. 2016;129(2):281\u20138.","journal-title":"J Neuro Oncol"},{"issue":"11","key":"937_CR64","doi-asserted-by":"crossref","first-page":"4074","DOI":"10.1158\/1078-0432.CCR-04-2550","volume":"11","author":"C Mawrin","year":"2005","unstructured":"Mawrin C, Sasse T, Kirches E, Kropf S, Schneider T, Grimm C, et al. Different activation of mitogen-activated protein kinase and Akt signaling is associated with aggressive phenotype of human meningiomas. Clin Cancer Res. 2005;11(11):4074\u201382.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"937_CR65","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s00428-014-1641-3","volume":"465","author":"EA El-Habr","year":"2014","unstructured":"El-Habr EA, Levidou G, Trigka EA, Sakalidou J, Piperi C, Chatziandreou I, et al. Complex interactions between the components of the PI3K\/AKT\/mTOR pathway, and with components of MAPK, JAK\/STAT and Notch-1 pathways, indicate their involvement in meningioma development. Virchows Archiv. 2014;465(4):473\u201385.","journal-title":"Virchows Archiv"},{"issue":"5","key":"937_CR66","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1093\/neuonc\/nov316","volume":"18","author":"M Abedalthagafi","year":"2016","unstructured":"Abedalthagafi M, Bi WL, Aizer AA, Merrill PH, Brewster R, Agarwalla PK, et al. Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma. Neuro Oncol. 2016;18(5):649\u201355.","journal-title":"Neuro Oncol"},{"issue":"17","key":"937_CR67","doi-asserted-by":"crossref","first-page":"17278","DOI":"10.1074\/jbc.C400063200","volume":"279","author":"LG Xu","year":"2004","unstructured":"Xu LG, Li LY, Shu HB. TRAF7 potentiates MEKK3-induced AP1 and CHOP activation and induces apoptosis. J Biol Chem. 2004;279(17):17278\u201382.","journal-title":"J Biol Chem"},{"issue":"3","key":"937_CR68","first-page":"345","volume":"19","author":"J Boetto","year":"2017","unstructured":"Boetto J, Bielle F, Sanson M, Peyre M, Kalamarides M. SMO mutation status defines a distinct and frequent molecular subgroup in olfactory groove meningiomas. Neuro Oncol. 2017;19(3):345\u201351.","journal-title":"Neuro Oncol"},{"issue":"7\u20138","key":"937_CR69","doi-asserted-by":"crossref","first-page":"262","DOI":"10.2119\/molmed.2010.00005","volume":"16","author":"I Laurendeau","year":"2010","unstructured":"Laurendeau I, Ferrer M, Garrido D, D\u2019Haene N, Ciavarelli P, Basso A, et al. Gene expression profiling of the hedgehog signaling pathway in human meningiomas. Mol Med. 2010;16(7\u20138):262\u201370.","journal-title":"Mol Med"},{"issue":"2","key":"937_CR70","first-page":"273","volume":"13","author":"JP Kalala","year":"2005","unstructured":"Kalala JP, Maes L, Vandenbroecke C, de Ridder L. The hTERT protein as a marker for malignancy in meningiomas. Oncol Rep. 2005;13(2):273\u20137.","journal-title":"Oncol Rep"},{"issue":"2","key":"937_CR71","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/bpa.12110","volume":"24","author":"S Goutagny","year":"2014","unstructured":"Goutagny S, Nault JC, Mallet M, Henin D, Rossi JZ, Kalamarides M. High incidence of activating TERT promoter mutations in meningiomas undergoing malignant progression. Brain Pathol. 2014;24(2):184\u20139.","journal-title":"Brain Pathol"},{"issue":"5","key":"937_CR72","doi-asserted-by":"crossref","first-page":"djv377","DOI":"10.1093\/jnci\/djv377","volume":"108","author":"F Sahm","year":"2015","unstructured":"Sahm F, Schrimpf D, Olar A, Koelsche C, Reuss D, Bissel J, et al. TERT promoter mutations and risk of recurrence in meningioma. J Natl Cancer Inst. 2015;108(5):djv377.","journal-title":"J Natl Cancer Inst"},{"issue":"65","key":"937_CR73","doi-asserted-by":"crossref","first-page":"109228","DOI":"10.18632\/oncotarget.22650","volume":"8","author":"TA Juratli","year":"2017","unstructured":"Juratli TA, Thiede C, Koerner MVA, Tummala SS, Daubner D, Shankar GM, et al. Intratumoral heterogeneity and TERT promoter mutations in progressive\/higher-grade meningiomas. Oncotarget. 2017;8(65):109228\u201337.","journal-title":"Oncotarget."},{"issue":"5","key":"937_CR74","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s00401-018-1899-7","volume":"136","author":"TA Juratli","year":"2018","unstructured":"Juratli TA, McCabe D, Nayyar N, Williams EA, Silverman IM, Tummala SS, et al. DMD genomic deletions characterize a subset of progressive\/higher-grade meningiomas with poor outcome. Acta Neuropathol. 2018;136(5):779\u201392.","journal-title":"Acta Neuropathol"},{"issue":"3","key":"937_CR75","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s11060-018-2912-7","volume":"139","author":"A Biczok","year":"2018","unstructured":"Biczok A, Kraus T, Suchorska B, Terpolilli NA, Thorsteinsdottir J, Giese A, et al. TERT promoter mutation is associated with worse prognosis in WHO grade II and III meningiomas. J Neuro-Oncol. 2018;139(3):671\u20138.","journal-title":"J Neuro-Oncol"},{"issue":"12","key":"937_CR76","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1093\/neuonc\/noy104","volume":"20","author":"S Spiegl-Kreinecker","year":"2018","unstructured":"Spiegl-Kreinecker S, Lotsch D, Neumayer K, Kastler L, Gojo J, Pirker C, et al. TERT promoter mutations are associated with poor prognosis and cell immortalization in meningioma. Neuro Oncol. 2018;20(12):1584\u201393.","journal-title":"Neuro Oncol"},{"issue":"11","key":"937_CR77","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1093\/neuonc\/nox094","volume":"19","author":"GM Shankar","year":"2017","unstructured":"Shankar GM, Santagata S. BAP1 mutations in high-grade meningioma: implications for patient care. Neuro Oncol. 2017;19(11):1447\u201356.","journal-title":"Neuro Oncol"},{"issue":"4","key":"937_CR78","first-page":"535","volume":"19","author":"GM Shankar","year":"2017","unstructured":"Shankar GM, Abedalthagafi M, Vaubel RA, Merrill PH, Nayyar N, Gill CM, et al. Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas. Neuro Oncol. 2017;19(4):535\u201345.","journal-title":"Neuro Oncol"},{"key":"937_CR79","doi-asserted-by":"publisher","unstructured":"Phillips JJ, Gong H, Chen K, et al. The genetic landscape of anaplastic pleomorphic xanthoastrocytoma. Brain Pathol. 2019;29(1):85\u201396. https:\/\/doi.org\/10.1111\/bpa.12639.","DOI":"10.1111\/bpa.12639"},{"issue":"1","key":"937_CR80","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1093\/neuonc\/nox132","volume":"20","author":"K Aoki","year":"2018","unstructured":"Aoki K, Nakamura H, Suzuki H, Matsuo K, Kataoka K, Shimamura T, et al. Prognostic relevance of genetic alterations in diffuse lower-grade gliomas. Neuro Oncol. 2018;20(1):66\u201377.","journal-title":"Neuro Oncol."},{"key":"937_CR81","doi-asserted-by":"publisher","unstructured":"Guyot A, Duchesne M, Robert S, et al. Analysis of CDKN2A gene alterations in recurrent and non-recurrent meningioma. J Neuro-Oncol. 2019;145(3):449\u201359. https:\/\/doi.org\/10.1007\/s11060-019-03333-6.","DOI":"10.1007\/s11060-019-03333-6"},{"key":"937_CR82","unstructured":"Kim H, Park K-J, Ryu B-K, Park D-H, Kong D-S, Chong K, et al. Forkhead box M1 (FOXM1) transcription factor is a key oncogenic driver of aggressive human meningioma progression.n\/a(n\/a)."},{"issue":"3","key":"937_CR83","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s00401-013-1093-x","volume":"125","author":"DE Reuss","year":"2013","unstructured":"Reuss DE, Piro RM, Jones DT, Simon M, Ketter R, Kool M, et al. Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations. Acta Neuropathol. 2013;125(3):351\u20138.","journal-title":"Acta Neuropathol"},{"issue":"7","key":"937_CR84","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/modpathol.2016.81","volume":"29","author":"S Yuzawa","year":"2016","unstructured":"Yuzawa S, Nishihara H, Yamaguchi S, Mohri H, Wang L, Kimura T, et al. Clinical impact of targeted amplicon sequencing for meningioma as a practical clinical-sequencing system. Mod Pathol. 2016;29(7):708\u201316.","journal-title":"Mod Pathol"},{"issue":"4","key":"937_CR85","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1152\/physrev.00058.2009","volume":"90","author":"BB McConnell","year":"2010","unstructured":"McConnell BB, Yang VW. Mammalian Kruppel-like factors in health and diseases. Physiol Rev. 2010;90(4):1337\u201381.","journal-title":"Physiol Rev"},{"issue":"4","key":"937_CR86","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.cell.2006.07.024","volume":"126","author":"K Takahashi","year":"2006","unstructured":"Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126(4):663\u201376.","journal-title":"Cell."},{"issue":"10","key":"937_CR87","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1038\/ng.3651","volume":"48","author":"VE Clark","year":"2016","unstructured":"Clark VE, Harmanci AS, Bai H, Youngblood MW, Lee TI, Baranoski JF, et al. Recurrent somatic mutations in POLR2A define a distinct subset of meningiomas. Nat Genet. 2016;48(10):1253\u20139.","journal-title":"Nat Genet"},{"issue":"3","key":"937_CR88","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s00401-017-1678-x","volume":"133","author":"A Olar","year":"2017","unstructured":"Olar A, Wani KM, Wilson CD, Zadeh G, DeMonte F, Jones DT, et al. Global epigenetic profiling identifies methylation subgroups associated with recurrence-free survival in meningioma. Acta Neuropathol. 2017;133(3):431\u201344.","journal-title":"Acta Neuropathol"},{"issue":"7","key":"937_CR89","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1093\/neuonc\/noz061","volume":"21","author":"F Nassiri","year":"2019","unstructured":"Nassiri F, Mamatjan Y, Suppiah S, Badhiwala JH, Mansouri S, Karimi S, et al. DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management. Neuro Oncol. 2019;21(7):901\u201310.","journal-title":"Neuro Oncol."},{"issue":"6","key":"937_CR90","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1007\/s00401-018-1844-9","volume":"135","author":"LM Katz","year":"2018","unstructured":"Katz LM, Hielscher T, Liechty B, Silverman J, Zagzag D, Sen R, et al. Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence. Acta Neuropathol. 2018;135(6):955\u201363.","journal-title":"Acta Neuropathol"},{"issue":"5","key":"937_CR91","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1016\/j.ajpath.2012.07.033","volume":"181","author":"PH Domingues","year":"2012","unstructured":"Domingues PH, Teodosio C, Ortiz J, Sousa P, Otero A, Maillo A, et al. Immunophenotypic identification and characterization of tumor cells and infiltrating cell populations in meningiomas. Am J Pathol. 2012;181(5):1749\u201361.","journal-title":"Am J Pathol"},{"key":"937_CR92","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jocn.2018.08.023","volume":"57","author":"MD Johnson","year":"2018","unstructured":"Johnson MD. PD-L1 expression in meningiomas. J Clin Neurosci. 2018;57:149\u201351.","journal-title":"J Clin Neurosci"},{"issue":"3","key":"937_CR93","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s11060-016-2256-0","volume":"130","author":"SJ Han","year":"2016","unstructured":"Han SJ, Reis G, Kohanbash G, Shrivastav S, Magill ST, Molinaro AM, et al. Expression and prognostic impact of immune modulatory molecule PD-L1 in meningioma. J Neuro-Oncol. 2016;130(3):543\u201352.","journal-title":"J Neuro-Oncol"},{"issue":"7","key":"937_CR94","doi-asserted-by":"crossref","first-page":"4704","DOI":"10.18632\/oncotarget.3082","volume":"6","author":"Z Du","year":"2015","unstructured":"Du Z, Abedalthagafi M, Aizer AA, McHenry AR, Sun HH, Bray M-A, et al. Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma. Oncotarget. 2015;6(7):4704\u201316.","journal-title":"Oncotarget."},{"key":"937_CR95","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.anndiagpath.2019.05.005","volume":"41","author":"S Kintsler","year":"2019","unstructured":"Kintsler S, Cassataro MA, Drosch M, Holenya P, Knuechel R, Braunschweig T. Expression of programmed death ligand (PD-L1) in different tumors. Comparison of several current available antibody clones and antibody profiling. Ann Diagn Pathol. 2019;41:24\u201337.","journal-title":"Ann Diagn Pathol"},{"key":"937_CR96","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41525-017-0014-7","volume":"2","author":"WL Bi","year":"2017","unstructured":"Bi WL, Greenwald NF, Abedalthagafi M, Wala J, Gibson WJ, Agarwalla PK, et al. Genomic landscape of high-grade meningiomas. NPJ Genom Med. 2017;2:15.","journal-title":"NPJ Genom Med"},{"key":"937_CR97","doi-asserted-by":"publisher","unstructured":"Dunn IF, Du Z, Touat M, Sisti MB, Wen PY, Umeton R, et al. Mismatch repair deficiency in high-grade meningioma: a rare but recurrent event associated with dramatic immune activation and clinical response to PD-1 blockade. JCO Precis Oncol. 2018. https:\/\/doi.org\/10.1200\/PO.18.00190.","DOI":"10.1200\/PO.18.00190"},{"key":"937_CR98","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jocn.2016.11.011","volume":"37","author":"E Gelerstein","year":"2017","unstructured":"Gelerstein E, Berger A, Jonas-Kimchi T, Strauss I, Kanner AA, Blumenthal DT, et al. Regression of intracranial meningioma following treatment with nivolumab: case report and review of the literature. J Clin Neurosci. 2017;37:51\u20133.","journal-title":"J Clin Neurosci"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-020-00937-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-020-00937-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-020-00937-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,3]],"date-time":"2021-07-03T00:31:29Z","timestamp":1625272289000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-020-00937-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,3]]},"references-count":98,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["937"],"URL":"https:\/\/doi.org\/10.1007\/s11912-020-00937-4","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,3]]},"assertion":[{"value":"3 July 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Christine Cordova is a co-investigator of NCT03971461. She did not receive research funding NCT03971461. Sylvia C. Kurz is study chair of NCT03971461, a study funded by Advanced Accelerator Applications evaluating Lutathera for advanced meningiomas.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"84"}}